Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenus
223
223
183
169
198
133
Croissance des revenus (H/H)
22%
22%
8%
-15%
49%
18%
Coût des ventes
92
92
77
79
74
60
Bénéfice brut
131
131
105
90
123
73
Vente, Général et Administration
188
178
158
155
157
161
Recherche et développement
97
97
98
103
64
75
Frais d'exploitation
286
275
257
259
222
237
Autres revenus (charges) non opérationnels
2
--
--
--
--
--
Bénéfice avant impôts
-139
-139
-139
-149
-83
-166
Charge d'impôt sur le revenu
5
5
6
4
7
1
Bénéfice net
-145
-145
-146
-154
-91
-167
Croissance du bénéfice net
-1%
-1%
-5%
69%
-46%
174%
Actions en circulation (diluées)
963.99
960.98
897.79
833.96
823.74
731.93
Variation des actions (H-H)
3%
7%
8%
1%
13%
-10%
EPS (dilué)
-0.15
-0.15
-0.16
-0.18
-0.11
-0.22
Croissance du EPS
-7%
-7%
-12%
68%
-52%
204%
Flux de trésorerie libre
-116
-116
-158
-164
-91
-84
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
58.74%
58.74%
57.37%
53.25%
62.12%
54.88%
Marge opérationnelle
-69.5%
-64.57%
-83.06%
-99.4%
-49.49%
-123.3%
Marge bénéficiaire
-65.02%
-65.02%
-79.78%
-91.12%
-45.95%
-125.56%
Marge du flux de trésorerie libre
-52.01%
-52.01%
-86.33%
-97.04%
-45.95%
-63.15%
EBITDA
-106
-95
-109
-127
-67
-140
Marge EBITDA
-47.53%
-42.6%
-59.56%
-75.14%
-33.83%
-105.26%
D&A pour le résultat opérationnel
49
49
43
41
31
24
EBIT
-155
-144
-152
-168
-98
-164
Marge EBIT
-69.5%
-64.57%
-83.06%
-99.4%
-49.49%
-123.3%
Taux d'imposition effectif
-3.59%
-3.59%
-4.31%
-2.68%
-8.43%
-0.6%
Follow-Up Questions
Oxford Nanopore Technologies PLC'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Oxford Nanopore Technologies PLC'in toplam varlıkları $622 olup, net perte $-145'dir.
ONTTF'ün temel finansal oranları nelerdir?
Oxford Nanopore Technologies PLC'in cari oranı 3.91, net kâr marjı -65.02, hisse başına satış $0.23'dir.
Oxford Nanopore Technologies PLC'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Le segment de revenus le plus important est Oxford Nanopore Technologies PLC, avec un chiffre d'affaires de Life Science Research Tools lors du dernier rapport de résultats. En termes géographiques, Europe, Middle East, Africa, and India est le marché principal pour Oxford Nanopore Technologies PLC, avec un chiffre d'affaires de 74,037,000.
Oxford Nanopore Technologies PLC kârlı mı?
non, son mali tablolara göre Oxford Nanopore Technologies PLC'in net perte $-145'dir.
Oxford Nanopore Technologies PLC'in herhangi bir yükümlülüğü var mı?